thalidomide has been researched along with Nephrogenic Systemic Fibrosis in 1 studies
Thalidomide: A piperidinyl isoindole originally introduced as a non-barbiturate hypnotic, but withdrawn from the market due to teratogenic effects. It has been reintroduced and used for a number of immunological and inflammatory disorders. Thalidomide displays immunosuppressive and anti-angiogenic activity. It inhibits release of TUMOR NECROSIS FACTOR-ALPHA from monocytes, and modulates other cytokine action.
thalidomide : A racemate comprising equimolar amounts of R- and S-thalidomide.
2-(2,6-dioxopiperidin-3-yl)-1H-isoindole-1,3(2H)-dione : A dicarboximide that is isoindole-1,3(2H)-dione in which the hydrogen attached to the nitrogen is substituted by a 2,6-dioxopiperidin-3-yl group.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Osseous metaplasia has recently been described in several cases of nephrogenic systemic fibrosis, sometimes in association with unusual clinical features such as painful hyperkeratotic spicules, palpable bony masses, and disease regression." | 1.36 | Osseous metaplasia late in the course of nephrogenic systemic fibrosis. ( Bayliss, SJ; Berk, DR; Lu, D; Miller, A; Scarlett, D; Wippold, FJ, 2010) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Berk, DR | 1 |
| Miller, A | 1 |
| Scarlett, D | 1 |
| Wippold, FJ | 1 |
| Bayliss, SJ | 1 |
| Lu, D | 1 |
1 other study available for thalidomide and Nephrogenic Systemic Fibrosis
| Article | Year |
|---|---|
Osseous metaplasia late in the course of nephrogenic systemic fibrosis.
Topics: Adult; Analgesics; Calcinosis; Disease Progression; Female; gamma-Aminobutyric Acid; Humans; Hydroxy | 2010 |